PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34596810-0 2021 Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways. regorafenib 64-75 AKT serine/threonine kinase 1 Homo sapiens 137-140 34596810-12 2021 In addition, results revealed that our novel combination of catalpol and regorafenib showed potent synergistic anti-tumour effect via suppressing both of PI3K/p-Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways and their downstreams. regorafenib 73-84 AKT serine/threonine kinase 1 Homo sapiens 161-164 34596810-13 2021 CONCLUSION: Catalpol and/or regorafenib markedly suppressed PI3K/p-Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways and consequently showed potent anti-tumour effects against HCC. regorafenib 28-39 AKT serine/threonine kinase 1 Homo sapiens 67-70 35126712-8 2022 It has been reported that AKT signaling is activated in regorafenib-resistant cancer cells and plays a crucial role in the regulation of cellular sensitivity to regorafenib. regorafenib 56-67 AKT serine/threonine kinase 1 Homo sapiens 26-29 35244188-11 2022 Co-treatment with harmine and either regorafenib or sorafenib also promoted cell death via the STAT3/HIF-1alpha/AKT signaling pathway under hypoxia using PI staining and western blotting. regorafenib 37-48 AKT serine/threonine kinase 1 Homo sapiens 112-115 35502476-0 2022 Regorafenib induces the apoptosis of gastrointestinal cancer-associated fibroblasts by inhibiting AKT phosphorylation. regorafenib 0-11 AKT serine/threonine kinase 1 Homo sapiens 98-101 35502476-10 2022 Furthermore, Western blot results showed that regorafenib down-regulated the expression of B-cell lymphoma-2 (Bcl-2) and concurrently up-regulated the expression of Bcl-2-associated X (Bax), and regorafenib inhibited the phosphorylation pathway of AKT in CAFs. regorafenib 46-57 AKT serine/threonine kinase 1 Homo sapiens 248-251 35502476-11 2022 In conclusion, our results provide a model in which regorafenib induces CAFs apoptosis by inhibiting the phosphorylation of AKT, and regorafenib affects macrophage infiltration by reducing the proportion of CAFs in tumor tissues. regorafenib 52-63 AKT serine/threonine kinase 1 Homo sapiens 124-127 35126712-8 2022 It has been reported that AKT signaling is activated in regorafenib-resistant cancer cells and plays a crucial role in the regulation of cellular sensitivity to regorafenib. regorafenib 161-172 AKT serine/threonine kinase 1 Homo sapiens 26-29 35126712-9 2022 In the present study, AKT was activated in regorafenib-treated cells, and harmine could suppress the activation of AKT and reinforce the anti-cancer effects of regorafenib via regulating AKT in liver cancer cells. regorafenib 43-54 AKT serine/threonine kinase 1 Homo sapiens 22-25 35126712-9 2022 In the present study, AKT was activated in regorafenib-treated cells, and harmine could suppress the activation of AKT and reinforce the anti-cancer effects of regorafenib via regulating AKT in liver cancer cells. regorafenib 160-171 AKT serine/threonine kinase 1 Homo sapiens 115-118 35126712-9 2022 In the present study, AKT was activated in regorafenib-treated cells, and harmine could suppress the activation of AKT and reinforce the anti-cancer effects of regorafenib via regulating AKT in liver cancer cells. regorafenib 160-171 AKT serine/threonine kinase 1 Homo sapiens 187-190 35126712-10 2022 These data indicated that harmine enhanced the anti-cancer effects of regorafenib on suppressing cell proliferation and inducing apoptosis in liver cancer cells via regulating the activation of AKT, and harmine plus regorafenib may be a potential therapeutic regimen for treating patients with liver cancer. regorafenib 70-81 AKT serine/threonine kinase 1 Homo sapiens 194-197 31163381-10 2019 Furthermore, we also found the suppression of AKT/NF-kappaB signaling was required for regorafenib inhibited expression of progression-related and invasion-related proteins. regorafenib 87-98 AKT serine/threonine kinase 1 Homo sapiens 46-49 32457362-0 2020 Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. regorafenib 0-11 AKT serine/threonine kinase 1 Homo sapiens 100-103 32457362-7 2020 Regorafenib treatment inhibits known receptor tyrosine kinase targets RET and PDGFRbeta and intracellular signalling through the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. regorafenib 0-11 AKT serine/threonine kinase 1 Homo sapiens 144-147 31501414-5 2019 Moreover, CCR2-mediated regorafenib tolerance was demonstrated to be associated with AKT/GSK3beta-regulated beta-catenin stabilization. regorafenib 24-35 AKT serine/threonine kinase 1 Homo sapiens 85-88 31163381-11 2019 Our finding indicated apoptosis induction and suppression of AKT/NF-kappaB signaling were associated with regorafenib-inhibited progression of NSCLC in vitro and in vivo. regorafenib 106-117 AKT serine/threonine kinase 1 Homo sapiens 61-64 31238539-7 2019 In these studies, we also indicated that regorafenib suppressed cell growth by prompting apoptosis of osteosarcoma cells, which is mediated through inactivation of ERK and AKT signaling pathways. regorafenib 41-52 AKT serine/threonine kinase 1 Homo sapiens 172-175 31238539-10 2019 In sum, we suggest that regorafenib has potential to suppress osteosarcoma progression via inactivation of AKT and ERK mediated signaling pathway. regorafenib 24-35 AKT serine/threonine kinase 1 Homo sapiens 107-110 30929918-9 2019 Furthermore, LSD1 suppressed by SP2590 or tranylcypromine could alleviate the activated p-AKT (ser473) induced by regorafenib in HCC cells. regorafenib 114-125 AKT serine/threonine kinase 1 Homo sapiens 90-93 29609689-6 2018 Moreover, the activation of Akt/mTOR signaling was inhibited by regorafenib pre-incubation. regorafenib 64-75 AKT serine/threonine kinase 1 Homo sapiens 28-31 29783729-8 2018 The mechanisms underlying the positive effects of combining CGA and Regorafenib were also addressed and an increased inhibition of MAPK (mitogen-activated protein kinase)and PI3K/Akt/mTORC (phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling was observed. regorafenib 68-79 AKT serine/threonine kinase 1 Homo sapiens 179-182 29783729-8 2018 The mechanisms underlying the positive effects of combining CGA and Regorafenib were also addressed and an increased inhibition of MAPK (mitogen-activated protein kinase)and PI3K/Akt/mTORC (phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling was observed. regorafenib 68-79 AKT serine/threonine kinase 1 Homo sapiens 227-230 29359239-5 2018 Regorafenib overcomes the growth advantage conferred by a stroma cell MM and an endothelial cell MM, co-culture systems, and abrogates growth factor-stimulated MEK, ERK, and AKT phosphorylation at nanomolar to micromolar concentrations. regorafenib 0-11 AKT serine/threonine kinase 1 Homo sapiens 174-177 26419617-5 2016 Examination of intracellular signaling found that Akt signaling was activated in Reg-R-SW480 cells but not in wild-type SW480 cells, after regorafenib treatment as measured by Western Blot. regorafenib 139-150 AKT serine/threonine kinase 1 Homo sapiens 50-53 28978118-6 2017 The combined treatment with regorafenib and silybin induced synergistic anti-proliferative and apoptotic effects by blocking PI3K/AKT/mTOR intracellular pathway. regorafenib 28-39 AKT serine/threonine kinase 1 Homo sapiens 130-133 28166200-8 2017 Surprisingly, attenuation of MARCKS using the MPS (MARCKS phosphorylation site domain) peptide synergistically interacted with regorafenib treatment and decreased survival of kidney cancer cells through inactivation of AKT and mTOR. regorafenib 127-138 AKT serine/threonine kinase 1 Homo sapiens 219-222 28000898-4 2017 Inhibitors of various kinases including AKT, c-Jun N-terminal kinase (JNK), P38 and extracellular signal-regulated kinase (ERK) were used to evaluate the mechanism of regorafenib-induced NF-kappaB inactivation. regorafenib 167-178 AKT serine/threonine kinase 1 Homo sapiens 40-43 25838391-5 2015 The combined treatment with cetuximab and regorafenib induced synergistic antiproliferative and apoptotic effects in cetuximab-resistant cell lines by blocking MAPK and AKT pathways. regorafenib 42-53 AKT serine/threonine kinase 1 Homo sapiens 169-172 25132955-14 2014 Western immunoblotting showed a mild reduction in KIT and AKT activation only in regorafenib treated tumours. regorafenib 81-92 AKT serine/threonine kinase 1 Homo sapiens 58-61 23877009-1 2013 The present studies were undertaken to determine whether the multikinase inhibitors sorafenib/regorafenib cooperated with clinically relevant , phosphatidyl inositol 3 kinase (PI3K)-thymoma viral proto-oncogene (AKT) inhibitors to kill tumor cells. regorafenib 94-105 AKT serine/threonine kinase 1 Homo sapiens 212-215